Relvar 100 Ellipta Special Drug Use Investigation (COPD, Long-term)

Trial Profile

Relvar 100 Ellipta Special Drug Use Investigation (COPD, Long-term)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Vilanterol/fluticasone furoate (Primary)
  • Indications Chronic bronchitis; Chronic obstructive pulmonary disease; Emphysema
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 Jul 2018 Status changed to recruiting.
    • 20 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top